CN115120569A - Method for removing static electricity among micro-pills - Google Patents
Method for removing static electricity among micro-pills Download PDFInfo
- Publication number
- CN115120569A CN115120569A CN202210792157.7A CN202210792157A CN115120569A CN 115120569 A CN115120569 A CN 115120569A CN 202210792157 A CN202210792157 A CN 202210792157A CN 115120569 A CN115120569 A CN 115120569A
- Authority
- CN
- China
- Prior art keywords
- pellets
- static electricity
- hydroxypropyl cellulose
- pellet
- spraying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000003068 static effect Effects 0.000 title claims abstract description 40
- 230000005611 electricity Effects 0.000 title claims abstract description 39
- 239000006187 pill Substances 0.000 title claims description 3
- 239000008188 pellet Substances 0.000 claims abstract description 83
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 31
- 239000011248 coating agent Substances 0.000 claims abstract description 31
- 238000000576 coating method Methods 0.000 claims abstract description 31
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 31
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 31
- 238000005507 spraying Methods 0.000 claims abstract description 29
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000007599 discharging Methods 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 abstract description 4
- 239000004698 Polyethylene Substances 0.000 abstract description 3
- -1 polyethylene Polymers 0.000 abstract description 3
- 229920000573 polyethylene Polymers 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003844 drug implant Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960000197 esomeprazole magnesium Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Abstract
The invention belongs to the field of pharmaceutical preparations, and discloses a method for removing static electricity among pellets, which comprises the following steps: after coating the pellets, spraying a hydroxypropyl cellulose solution according to the condition that the dosage of the hydroxypropyl cellulose is 2-5 wt% of the mass of the pellets, controlling the temperature of the material to be 40-50 ℃ when spraying the hydroxypropyl cellulose solution, and mixing the pellets with a small amount of talcum powder after drying and discharging the pellets. The invention solves the problem of static electricity among the pellets by spraying hydroxypropyl cellulose and mixing a small amount of talcum powder, the pellets are not adhered to a medical polyethylene film bag after being discharged, the loss in the transfer process caused by static electricity is reduced, the convenience in the use and transfer process of the pellets is increased, and the problems of unstable pellet loading and unqualified medicine quality caused by static electricity in the next step of dose distribution are solved.
Description
Technical Field
The invention belongs to the field of medicinal preparations, relates to a pellet preparation, and particularly relates to a method for removing static electricity among pellets.
Background
The Pellets (Pellets) are spherical or spheroidal oral preparations with a diameter of 0.2-1.5 mm. The pellet has the advantages of good fluidity, easy capsule filling, small filling quantity difference and the like, is more applied to long-acting and sustained and controlled release dosage forms in the current pharmaceutical technology, and is widely applied to pellet coating. And because the pellet is small in size, when the preparation is coated and loaded, the rotary coating or rolling coating cannot be carried out, and the main stream coating form is still fluidized bed bottom spraying coating.
In the process of preparing the pellets, because the pellets are small, the pellets are continuously rubbed, the pellets can generate static electricity when being impacted with the surface of equipment, and the static electricity phenomenon is particularly obvious in the drying stage after coating, the discharging and bagging process and the next process step such as the capsule filling stage, so that the pellets are adhered to a medical polyethylene film bag, the use and transfer process is extremely inconvenient, and even the problem of unqualified medicine quality caused by unstable pellet loading during dosage can be caused.
The existing methods for solving the static electricity include increasing humidity, reducing temperature, grounding wires, adding static electricity liquid and the like, and the methods are not very feasible when used for solving the static electricity of the medicine. Firstly, increasing the humidity and reducing the temperature can affect the original process parameters, possibly causing the pellets to be sticky; secondly, multiple tests prove that the grounding wire does not obviously improve the electrostatic problem of the pellets; finally, while electrostatic liquids can remove static electricity, most of the existing electrostatic liquids are inedible and therefore not feasible for use in medicine.
In addition, the pharmaceutical industry has also been directed to removing static electricity by adding talc to the coating formulation or by blending talc after discharge, but both methods use larger amounts of talc. Meanwhile, the talcum powder has a pore-forming agent in the coating liquid, which affects the release of the medicine; although the talc powder mixed after discharging has the function of reducing static electricity and can not absolutely eliminate the static electricity, the dosage is at least 0.5 percent of the mass of the pellet, and the problem of talc powder deposition is easy to occur after mixing.
Disclosure of Invention
The invention aims to solve the problem of pellet static electricity, and provides a method for removing the static electricity among the pellets, so that the pellets are beneficial to the next process operation (such as capsule filling), the loading difference of the pellets is ensured, and the quality of the medicine is ensured.
The technical problem to be solved by the invention can be realized by the following technical scheme:
a method of removing inter-pellet static electricity comprising: after coating the pellets, spraying a hydroxypropyl cellulose solution according to the condition that the dosage of the hydroxypropyl cellulose is 2-5 wt% of the mass of the pellets, controlling the temperature of the material to be 40-50 ℃ when spraying the hydroxypropyl cellulose solution, and mixing the pellets with a small amount of talcum powder after drying and discharging the pellets.
The concentration of the hydroxypropyl cellulose solution is 3 to 5 percent by weight.
As the preferred technical scheme of the method for removing the static electricity among the pellets, the hydroxypropyl cellulose solution can be added with an anti-sticking agent to reduce the viscosity of the hydroxypropyl cellulose solution, and the concentration of the anti-sticking agent in the hydroxypropyl cellulose solution is 3-5 percent by weight; the antisticking agent can be talcum powder.
As a further specific technical scheme of the method for removing the static electricity among the pellets, the pellet coating and the hydroxypropyl cellulose solution spraying are carried out in a fluidized bed; the method comprises the following steps: after coating the pellets, spraying hydroxypropyl cellulose solution in a fluidized bed by adopting a fluidized bed bottom spraying technology for coating, wherein the air inlet temperature is set to be 55 +/-5 ℃, and the air volume is 100-200 m 3 The atomization pressure is 1.5-3.0 kg/cm 2 Control ofThe spraying speed is 2-5 g/min, and the material temperature is controlled at 40-50 ℃; and after the coating is finished, setting the air inlet temperature of the fluidized bed to be 40-50 ℃, drying and discharging.
After the pellets are dried and discharged, the dosage of the talcum powder is generally 0.1-0.3 wt% of the mass of the pellets (calculated by spraying the pellets with hydroxypropyl cellulose).
The pellet is a prazole drug pellet, and specifically can be an esomeprazole pellet.
It is another object of the present invention to provide the use of hydroxypropylcellulose for removing the static electricity between pellets.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention solves the problem of static electricity among the pellets by spraying hydroxypropyl cellulose and then mixing a small amount of talcum powder, the pellets are not adhered to a medical polyethylene film bag after being discharged, the loss in the transfer process caused by static electricity is reduced, the convenience in the use and transfer process of the pellets is increased, and the problems of unstable pellet loading and unqualified medicine quality caused by static electricity in the next step of dosage division are solved.
(2) The invention can prepare the micropills and coat the hydroxypropyl cellulose solution in the same equipment, has simple process and does not influence the drug release when being controlled within the required weight increment range.
Drawings
FIG. 1 is a graph comparing the electrostatic removal effect of pellets; the pellets obtained in example 1, example 2, comparative example 1, comparative example 2 and comparative example 3 were sequentially placed from left to right.
Detailed Description
The invention is further illustrated by the following examples, which are intended to be illustrative and not limiting.
The hydroxypropylcellulose used in the examples was HPC-L type product of Nippon soda.
The pellet (particle size is 500-700 μm) of the prazole medicine used in the embodiment refers to the prescription and preparation process of the Chinese patent CN1134666A embodiment 2, and the enteric-coated pellet is prepared by replacing magnesium omeprazole with the equivalent raw material esomeprazole magnesium.
Example 1
The materials were weighed according to the following formula:
the preparation method comprises the following steps: adding hydroxypropyl cellulose in the prescription amount into purified water in the prescription amount, stirring for dissolving to obtain coating solution (hydroxypropyl cellulose concentration is 4 wt%), adding the prazole drug pellets into a fluidized bed, starting bottom spraying of the fluidized bed, setting air inlet temperature at 55 deg.C and air volume at 120m 3 H, atomization pressure 2.0kg/cm 2 Controlling the spraying speed to be 2-4 g/min, controlling the material temperature to be 40-50 ℃, and performing spraying coating; and after coating, controlling the temperature of the fluidized bed material to be 40-50 ℃, drying for 30min, discharging, and adding 0.4g of talcum powder for mixing.
Example 2
The materials were weighed according to the following formula:
the preparation method comprises the following steps: adding hydroxypropyl cellulose in the amount of the prescription into purified water in the amount of the prescription, stirring for dissolving, adding talcum powder in the amount of the prescription, stirring uniformly to obtain a coating solution, adding the prazole drug pellets into a fluidized bed, starting the bottom spraying of the fluidized bed, setting the air inlet temperature at 55 ℃, and the air volume at 140m 3 H, atomization pressure 1.8kg/cm 2 Controlling the spraying speed to be 3-5 g/min, controlling the material temperature to be 40-50 ℃, and maintaining the stirring of the coating liquid to carry out spraying coating; and after coating, controlling the temperature of the fluidized bed material to be 40-50 ℃, drying for 30min, discharging, and adding 0.3g of talcum powder for mixing.
Example 3
The materials were weighed according to the following formula:
the preparation method comprises the following steps: adding hydroxypropyl cellulose in the prescription amount into purified water in the prescription amount, stirring for dissolving to obtain coating solution, adding the prazole drug pellets into a fluidized bed, starting the bottom spraying of the fluidized bed, setting the air inlet temperature at 55 ℃ and the air volume at 150m 3 H, atomization pressure 2.2kg/cm 2 Controlling the spraying speed to be 2-4 g/min, controlling the material temperature to be 40-50 ℃, and maintaining the stirring of the coating liquid to carry out spraying coating; and after coating, controlling the temperature of the fluidized bed material to be 40-50 ℃, drying for 30min, discharging, and adding 0.3g of talcum powder for mixing.
Comparative example 1
The materials were weighed according to the following formula:
mixing: 200g of prazole drug pellets
Talcum powder 1g
The preparation method comprises the following steps: adding talcum powder according to 0.5 percent of the mass of the prazole medicine pellets, and mixing to obtain the prazole medicine pellets.
Comparative example 2:
the materials were weighed according to the following formula:
mixing: 200g of prazole drug pellets
Talcum powder 4g
The preparation method comprises the following steps: adding talcum powder according to 2 percent of the mass of the prazole pellets, and mixing to obtain the prazole pellet.
Comparative example 3
Curing refers to the progressive film formation process that occurs from an aqueous dispersion by the coalescence of latex particles to form a coating. Static electricity removal means to remove the charges on the solid, liquid or even gas due to contact separation.
In view of the fact that the method of spraying hypromellose solution after coating the pellets is a common pellet curing method, the inventors replaced hypromellose with hypromellose in example 1 to observe the effect of removing static electricity.
The materials were weighed according to the following formula:
the preparation method comprises the following steps: adding hydroxypropyl methylcellulose in a prescription amount into purified water in a prescription amount, stirring and dissolving to obtain a coating solution, adding the prazole drug pellets into a fluidized bed, starting bottom spraying of the fluidized bed, setting the air inlet temperature to be 55 ℃, controlling the material temperature to be 40-50 ℃, and performing spray coating; after coating, controlling the temperature of the fluidized bed material to be 40-50 ℃, drying for 30min, and discharging; 0.4g of talc was added and mixed.
Investigation of static removal
In fig. 1, pellets without any treatment (i.e., pellets of a prazole drug), pellets obtained in example 1, example 2, comparative example 1, comparative example 2, and comparative example 3 are shown from left to right. It can be seen that the pellets which were not subjected to any treatment had a large static electricity, the sticking to the film bag was severe, the samples prepared in examples 1, 2 and 3 (not shown) had almost no static electricity, and no pellets were stuck to the film bag, whereas the static electricity removing effect was not significant in the samples prepared in comparative examples 1 and 3, and the phenomenon of the deposition of talc powder occurred in comparative example 2 because the amount of talc was as high as 2% although the static electricity was removed.
Release Rate investigation
The measuring method comprises the following steps: taking a sample (weighed according to 40mg of marked amount), taking a dissolution and release determination method (generally, 0931, method 1 of the second method), taking 300mL0.l mol/L hydrochloric acid as a dissolution medium, rotating at 100 revolutions per minute, operating according to the method, immediately adding 700mL of 0.086mol/L disodium hydrogen phosphate solution preheated to 37 +/-0.5 ℃ into each dissolution cup after 2 hours of operation according to the method, uniformly mixing, continuing operating according to the method, filtering about 10mL of solution after 30 minutes, precisely taking 5mL of filtrate, precisely adding 1mL0.25mol/L sodium hydroxide solution, shaking uniformly to serve as a sample solution; taking about 20mg of omeprazole reference substance, precisely weighing, placing in a 100mL measuring flask, adding 10mL of ethanol for dissolving, diluting to a scale with a pH 6.8 phosphate buffer solution (obtained by uniformly mixing 700mL of 0.086mol/L disodium hydrogen phosphate solution and 300mL of 0.1 mol/L hydrochloric acid solution), shaking up, precisely measuring 10mL, placing in a 50mL measuring flask, diluting to a scale with the pH 6.8 phosphate buffer solution, shaking up, precisely measuring 5mL, precisely adding 1mL of 0.25mol/L sodium hydroxide solution, shaking up to serve as the reference substance solution. The amount of elution was calculated according to the content method. The results are shown in Table 1.
TABLE 1 drug Release test results in pellets
As can be seen from table 1, there is no significant difference in the release of esomeprazole magnesium pellets prepared in examples 1-3 compared to pellets without any treatment.
Claims (9)
1. A method for removing static electricity among micro-pills is characterized in that: after coating the pellets, spraying a hydroxypropyl cellulose solution according to the weight of the hydroxypropyl cellulose accounting for 2-5% of the mass of the pellets, controlling the temperature of the materials at 40-50 ℃ when spraying the hydroxypropyl cellulose solution, and mixing the pellets with a small amount of talcum powder after drying and discharging.
2. The method for removing the inter-pellet static electricity according to claim 1, wherein: the concentration of the hydroxypropyl cellulose solution is 3 to 5 percent by weight.
3. The method for removing the inter-pellet static electricity according to claim 1, wherein: the anti-sticking agent is added into the hydroxypropyl cellulose solution, and the concentration of the anti-sticking agent in the hydroxypropyl cellulose solution is 3-5 wt%.
4. The method for removing the inter-pellet static electricity according to claim 3, wherein: the anti-sticking agent is talcum powder.
5. The method for removing the inter-pellet static electricity according to claim 1, wherein: coating the pellets and spraying the hydroxypropylcellulose solution to coat the pellets in a fluidized bed.
6. The method for removing the inter-pellet static electricity according to claim 5, wherein: and spraying hydroxypropyl cellulose solution by adopting a fluidized bed bottom spraying technology for coating.
7. The method for removing the inter-pellet static electricity according to claim 1, wherein: the dosage of the talcum powder is 0.1-0.3 wt% of the mass of the pellet.
8. The method for removing the inter-pellet static electricity according to claim 1, wherein: the pellet is a prazole drug pellet.
9. Use of hydroxypropylcellulose for removing electrostatic charge from pellets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210792157.7A CN115120569B (en) | 2022-07-07 | 2022-07-07 | Method for removing static electricity among micropills |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210792157.7A CN115120569B (en) | 2022-07-07 | 2022-07-07 | Method for removing static electricity among micropills |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115120569A true CN115120569A (en) | 2022-09-30 |
| CN115120569B CN115120569B (en) | 2023-11-28 |
Family
ID=83381616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210792157.7A Active CN115120569B (en) | 2022-07-07 | 2022-07-07 | Method for removing static electricity among micropills |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115120569B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134666A (en) * | 1994-07-08 | 1996-10-30 | 阿斯特拉公司 | Multiple unit tableted dosage form I |
| JPH11189768A (en) * | 1997-12-26 | 1999-07-13 | Kao Corp | Antistatic agent composition for chemical fiber |
| JP2000327837A (en) * | 1999-05-17 | 2000-11-28 | Asahi Chem Ind Co Ltd | Composition containing cellulose as antistatic agent |
| CN102697660A (en) * | 2012-06-04 | 2012-10-03 | 贵州景峰注射剂有限公司 | Method for eliminating static electricity in micro-pill room |
| CN104013580A (en) * | 2014-06-13 | 2014-09-03 | 海南葫芦娃制药有限公司 | Lansoprazole pellet, capsule and preparation method thereof |
| CN104248766A (en) * | 2013-06-28 | 2014-12-31 | 重庆药友制药有限责任公司 | Coating solution containing ethyl cellulose and preparation method thereof |
| CN112516100A (en) * | 2020-12-31 | 2021-03-19 | 珠海润都制药股份有限公司 | Espressol omeprazole magnesium enteric-coated tablet and preparation method thereof |
| CN113101276A (en) * | 2021-03-11 | 2021-07-13 | 浙江康德药业集团股份有限公司 | Esciprazole magnesium enteric-coated pellet and capsule and preparation method thereof |
-
2022
- 2022-07-07 CN CN202210792157.7A patent/CN115120569B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134666A (en) * | 1994-07-08 | 1996-10-30 | 阿斯特拉公司 | Multiple unit tableted dosage form I |
| JPH11189768A (en) * | 1997-12-26 | 1999-07-13 | Kao Corp | Antistatic agent composition for chemical fiber |
| JP2000327837A (en) * | 1999-05-17 | 2000-11-28 | Asahi Chem Ind Co Ltd | Composition containing cellulose as antistatic agent |
| CN102697660A (en) * | 2012-06-04 | 2012-10-03 | 贵州景峰注射剂有限公司 | Method for eliminating static electricity in micro-pill room |
| CN104248766A (en) * | 2013-06-28 | 2014-12-31 | 重庆药友制药有限责任公司 | Coating solution containing ethyl cellulose and preparation method thereof |
| CN104013580A (en) * | 2014-06-13 | 2014-09-03 | 海南葫芦娃制药有限公司 | Lansoprazole pellet, capsule and preparation method thereof |
| CN112516100A (en) * | 2020-12-31 | 2021-03-19 | 珠海润都制药股份有限公司 | Espressol omeprazole magnesium enteric-coated tablet and preparation method thereof |
| CN113101276A (en) * | 2021-03-11 | 2021-07-13 | 浙江康德药业集团股份有限公司 | Esciprazole magnesium enteric-coated pellet and capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115120569B (en) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2147231C1 (en) | Intestinal duloxetine granules | |
| EP0452862B1 (en) | Spherical seed cores, spherical granules and process for production thereof | |
| JP3447042B2 (en) | Method for producing single substance spherical particles | |
| EP0616841B1 (en) | Production method for fine granulate | |
| CA2440010C (en) | Powder inhaler formulations | |
| RU2529798C2 (en) | Method of obtaining dabigatran-containing drug compounds | |
| Zeng et al. | The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate | |
| EP2216048A1 (en) | Spherical particle and method for producing the same | |
| SE522914C2 (en) | Enteral fluoxetine pills | |
| EP0958812B1 (en) | Spherical particle groups, process for preparing the same and spherical particulate pharmaceuticals using the same | |
| CN104352441A (en) | DMF (dimethyl fumarate) enteric-coated micropellet and preparation method thereof | |
| CN115120569A (en) | Method for removing static electricity among micro-pills | |
| JPH04230211A (en) | Method for coating active element with ph sensitive polymers | |
| CN110314152B (en) | Ibuprofen sustained-release pellet capsule and preparation method thereof | |
| CN105055350B (en) | A kind of preparation method of the tablet containing proton pump inhibitor | |
| CN114983973B (en) | Urapidil sustained-release capsule and preparation method thereof | |
| JP3910939B2 (en) | Single-substance spherical particles, foods and medicines using them, and methods for producing them | |
| CN111346064B (en) | Rivaroxaban tablet and preparation method thereof | |
| CN108542892B (en) | Preparation method of amoxicillin capsule | |
| CN107569473A (en) | A kind of Sustained Release Ambroxol Hydrochloride Capsules and preparation method thereof | |
| CN107569467A (en) | A kind of capsule preparations of stabilization containing dabigatran etexilate methanesulfonate and preparation method thereof | |
| CN113694041B (en) | Process for preparing medicinal sucrose pill core | |
| CN104434867A (en) | Composition of Pradaxa and preparation method thereof | |
| CN112618502B (en) | High-dissolution clotrimazole vaginal tablet and preparation process thereof | |
| WO2023139243A1 (en) | A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231106 Address after: No.36 Shuanggao Road, Gaochun Economic Development Zone, Nanjing, Jiangsu Applicant after: Jiangsu Zhongbang Pharmaceutical Co.,Ltd. Applicant after: Nanjing Red Sun Pharmaceutical Research Institute Co.,Ltd. Applicant after: SOUTHEAST University Address before: No.36 Shuanggao Road, Gaochun Economic Development Zone, Nanjing, Jiangsu Applicant before: Jiangsu Zhongbang Pharmaceutical Co.,Ltd. Applicant before: Nanjing Red Sun Pharmaceutical Research Institute Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |